Why the study?
In HFrEF patients with CRT, iron deficiency is associated with diminished reverse remodelling and poor functional improvement, partially related to impaired contractile force at higher heart rates.
Does intravenous ferric carboxymaltose improve left ventricular ejection fraction in HFrEF patients with incomplete reverse remodelling after CRT and iron deficiency?
Population
100 HFrEF patients with iron deficiency and incomplete reverse remodelling after CRT
Comparison
Intravenous ferric carboxymaltose vs intravenous placebo
Design
Multicentre prospective randomized double-blind controlled trial
Follow-up
3 month
Authors
Loading...
Tests IV iron for remodelling in iron-deficient HFrEF with incomplete CRT response; RCT will extend evidence on iron repletion.
Does intravenous ferric carboxymaltose improve left ventricular ejection fraction in HFrEF patients with incomplete reverse remodelling after CRT and iron deficiency?
The IRON-CRT trial is designed to evaluate whether intravenous ferric carboxymaltose improves cardiac reverse remodelling and contractility in HFrEF patients with iron deficiency and an incomplete response to CRT.
Martens et al. (2019) studied this question.